Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Robert C. Andrade | Chief Financial Officer | 846.31k | -- | 1975 |
| Mr. Jeffrey S. Hackman | CEO & Director | -- | -- | 1963 |
| Mr. Terry Evans | Chief Commercial Officer | -- | -- | -- |
| Dr. Pierre S. Sayad M.S., Ph.D. | Chief Medical Officer | -- | -- | -- |
| Ms. Christiana Cioffi M.B.A. | Chief Strategy Officer | -- | -- | -- |
| Mr. Mark Gowland | Controller | -- | -- | -- |
| Mr. Lei Fang | President of Pharstat Inc | -- | -- | -- |
Fennec Pharmaceuticals Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 32
Description
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Corporate Governance
Upcoming Events
May 12, 2025 at 12:30 PM UTC - May 19, 2025 at 12:30 PM UTC
Fennec Pharmaceuticals Inc. Earnings Date
Recent Events
Recent Events Information Not Available